Clinical Trial Update: Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating 6-month delamanid treatment for multidrug-resistant tuberculosis with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multidrug-resistant Tuberculosis
• Tuberculosis

Drugs mentioned

• Delamanid (delamanid)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Multidrug-resistant Tuberculosis | Phase 3 | Status: COMPLETED | Results posted: 2019-05-15